Targeted ultrasonic contrast agents for molecular imaging and therapy

Progress in Cardiovascular Diseases

Volumn 44, Issue 1, 2001, Pages 13-31

  Lanza, Gregory M ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; ALBUNEX; ASIALOGLYCOPROTEIN; CONTRAST MEDIUM; FLUOROCARBON; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; MRX 408; PEPTIDE; PERFLUTREN; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; BUBBLE; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG SPECIFICITY; DRUG TARGETING; FUNCTIONAL ANATOMY; FUTUROLOGY; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NON INVASIVE MEASUREMENT; OXYGENATOR; PATHOLOGICAL ANATOMY; PHAGE DISPLAY; QUANTITATIVE DIAGNOSIS;

EID: 0034860985     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2001.26440     Document Type: Article

References (87)

1. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy
2. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography
3. Pharmaceutical discovery and development: Nuclear and molecular imaging technologies recognized
4. Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent
5. Targeted contrast agents
6. Molecular imaging: Exploring the next frontier
7. Echocardiography of the aortic root
8. Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles
9. Targeting of ultrasound contrast material. An in vitro feasibility study
10. In vitro studies of a new thrombus-specific ultrasound contrast agent
11. A high-frequency continuous-wave Doppler ultrasound system for the detection of blood flow in the microcirculation
12. A novel site-targeted ultrasonic contrast agent with broad biomedical application
13. In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement
14. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes
15. Differential properties of organ-specific serum opsonins for liver and spleen macrophages
16. Gas-filled liposomes as echocardiographic contrast agents in rabbits with myocardial infarcts
17. Acoustically active lipospheres containing paclitaxel: A new therapeutic ultrasound contrast agent
18. Ultrasound enhances gene expression of liposomal transfection
19. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound
20. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients
21. Three-step tumor pre-targeting in lung cancer immunoscintigraphy
22. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: Preliminary results
23. Induction of in situ immune complexes in rat glomeruli using avidin, native cation macromolecule
24. Selection of high-affinity phage antibodies from phage display libraries
25. Antibody production without animals
26. Phage on display
27. Display cloning: Functional identification of natural product receptors using cDNA-phage display
28. Evaluation of new thrombus-specific ultrasound contrast agent
29. Pancreatic receptors: Initial feasibility studies with a targeted contrast agent for MR imaging
30. Preclinical assessment of hepatocyte-targeted MR contrast agents in stable human liver cell cultures
31. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats
32. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents
33. Receptor-directed contrast agents for MR imaging: Preclinical evaluation with affinity assays
34. Enhancement effects of a hepatocyte receptor-specific MR contrast agent in an animal model
35. Nitrogen-filled liposomes as a vascular US contrast agent: Preliminary evaluation
36. Gas-filled lipid bilayers as ultrasound contrast agents
37. Binding and lysing of blood clots using MRX-408
38. Enhanced visualiation of intravascular and left atrial appendage thrombus with the use of a thrombus-targeting ultrasonographic contrast agent (MRX-480A1): In vivo experimental echocardiographic studies
39. MRX 501: A novel ultrasound contrast agent with therapeutic properties
40. Cationic liposome-mediated transfection
41. Systemic gene expression after intravenous DNA delivery into adult mice
42. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo
43. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro
44. Targeting of ultrasound contrast material: An in vitro feasibility study
45. Microbubbles targeted to intracellular adhesion molecule-1 bind to activated cornary artery endothelial cells
46. Acoustic radiation force in vivo: A mechanism to assist targeting of microbubbles
47. Targeting and ultrasound imaging of microbubble-based contrast agents
48. Antileishmanial activity of antimonials entrapped in liposomes
49. Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs
50. Suppression of phagocytic function and phospholipid metabolism in macrophages by phosphatidylinositol liposomes
51. Ultrasound enhances PESDA linked oligonucleotide deposition into myocardial tissue
52. Enhanced delivery and effectiveness of antisense oligonucleotides when bound to intravenous perfluorocarbon-filled microbubbles: Effect of ultrasound and therapeutic implications
53. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury
54. Inhibition of carotid artery neointimal formation following balloon injury using ultrasound-targeted deposition of antisense to C-MYC protooncogene bound to intravenously delivered perfluorocarbon microbubbles
55. Detrimental effects of low frequency 20 kilohertz transthoracic ultrasound on coronary artery neointimal hyperplasia following balloon injury: 30 Day angiographic, histologic, and ultrasound intravascular observations
56. Intravenous antisense administered bound to perfluorocarbon exposed sonicated dextrose albumin microbubbles inhibits stenosis formation following coronary balloon injury
57. Development of inherently echogenic liposomes as an ultrasonic contrast agent
58. Destabilization of phosphatidylethanolamine-containing liposomes: Hexagonal phase and asymmetric membranes
59. Membrane fusion and inverted phases
60. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement
61. Development of echogenic, plasmid-incorporated, tissue-targeted cationic liposomes that can be used for directed gene delivery
62. In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy
63. Experimental determination of phase velocity of perfluorocarbons: Applications to targeted contrast agent
64. Enhancement of ultrasound surface reflectivity depends on the specific perfluorocarbons utilized to formulate nanoparticle emulsion contrast agents
65. Purification of human brain tissue factor
66. Human tissue factor: CDNA sequence and chromosome localization of the gene
67. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles
68. Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound
69. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-injured arteries in pigs
70. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury
71. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
72. Targeted magnetic resonance contrast agent for detection of thrombus
73. Molecular imaging of thrombus with a new targeted magnetic resonance contrast agent
74. Molecular characterization of thrombus using bimodal 1H/19F MR imaging with a novel fibrin-targeted nanoparticulate contrast agent
75. What is the evidence that tumors are angiogenesis dependent?
76. Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes
77. 3 blocks human breast cancer growth and angiogenesis in human skin
78. v gene expression in human melanoma tumorigenicity
79. 3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions
80. 3 integrin
81. Optical and acoustical dynamics of microbubble contrast agents inside neutrophils
82. 3 targeted nanoparticles
83. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
84. 3 integrin antagonists: A new class of tracers for tumor targeting
85. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrinand complement-mediated adherence to activated leukocytes
86. Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles
87. Experimental determination of phase velocity of perfluorocarbons: Applications to targeted contrast agents